Dr. Yi Wang

Dr. Wang is an early-stage life science startup operator, consultant, and angel investor, and a researcher. His experience blends business operations, startup fundraising, and scientific research in both the biotechnology and health data fields.

He has many years of startup business operating experience as a Co-Founder and CEO of a medical analysis software startup from Yale and as an entrepreneurial fellow at Yale Ventures, where he provided expertise in fundraising, operations, and strategy to Yale technologies in digital health and biotechnology assets. He was the VP of Business Development at Isolere Bio, a Duke University spinout focused on gene therapy biomanufacturing, where he developed business strategy, and forged relationships and drafted agreements for licensing and partnerships. At Eli Lilly, he worked on breast cancer drug strategy and developed post-PoC decision framework for pain drug candidates.

In addition to his startup operation experience, he has invested and led/participated in diligence for startups targeting indications such as autoimmune, diabetes, GI tract disease, and vascular graft under modalities including microorganisms, peptides, nanoparticles, and antibodies at San Diego-based NuFund (formerly San Diego Tech Coast Angels) and Indiana-based VisionTech Angels and Partners. During this research career as a tenured professor, he was recognized as "40 Under 40 in Public Health" by the Washington DC-based de Beaumont Foundation and was awarded the "Outstanding Individual Advancing Sustainability Award" by the Indianapolis Mayor's Office.

He attended the full-time MBA program as a Manning Scholar at Duke University. He received his Ph.D. in Environmental Health and Epidemiology at the University of Michigan School of Public Health, followed by his postdoctoral training at Brown University School of Public Health. Prior to his PhD research, he was a bench scientist and received his Master's degree in Toxicology at the University of California, Irvine, and his Bachelor's degree in Bioengineering at Shenyang Pharmaceutical University in China.